GenoBank.io, part of the Story ecosystem, is expanding its BioIP platform to register genomic data as digital assets that individuals can own, license, and monetize. The platform currently supports over 7,000 genomic accounts and 150 research partnerships, with $6.9 million in tokenized BioIP value. This innovation addresses the growing global genomics market, projected to reach $85 billion by 2030, by providing a secure infrastructure for AI-driven genomic data access and licensing. GenoBank’s technology allows controlled, micropayment-based access to sensitive genetic information, enhancing data privacy and creating new revenue opportunities for individuals and researchers alike.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
